Commentary

Beyond equity financing, early-stage technology and biotechnology businesses may still have a need for other forms of financing. In this 11th edition of Early Stage, Madison attorney Joe Boucher begins to run through the various business borrowing options....

The Enron scandal was symbolic of a wave of corporate malfeasance that shook the American business community and led to legislative fixes like Sarbanes-Oxley. In this edition of Boardroom Perspectives, Edgewood College business professor Denis Collins, who has written a book about the Enron debacle,...

The markets are deciding now who will lead the 21st century energy parade, but based on the Legislature's lack of support for Gov. Doyle's renewable energy program, Wisconsin's interest in marching is still unclear, writes Inside Wisconsin columnist Tom Still. In the words of colorful...

Most U.S. companies seem to have focused their growth efforts on China and India, but columnist Michael Rosen wants to remind them about Brazil. Rosen was dazzled by what he saw during a recent visit to Sao Paulo, and in this edition of Yer Biotech...

When will people realize that the network infrastructure of the United States is not a drum for socialism, but a much more critical instrument to strategically position and sustain this country in the world economy? asks columnist James Carlini. A national broadband policy should not...

It's generally a good idea to use a Private Placement Memorandum, or PPM, when offering securities to investors. In this edition of Private Placements, Michael Best & Friedrich attorneys Matt Storms and Dan Ghoca explain the content and the benefits of PPMs, including protection against...

Does anybody want to pay for Web-based services? Columnist Chris Shipley poses that question as she comments on the fate of Famster.com, which has moved to a subscription-only business model. In this edition of DEMO Letter, she hopes Famster becomes a model for user-paid Web...

The regulatory pathways for drugs (medicine) are quite different than those for devices (surgery), but convergent medical technologies will require a closer interplay between the two, according to Dr. Ogan Gurel, author of MedTech Futures. Despite technical and cultural challenges, and even though certain medical...